Sarah Cunningham

Dr. Sarah Cunningham

Department of Transfusion Medicine and Hemostaseology, University Hospital Erlangen, Erlangen, Bavaria, Germany
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

15 February 2019 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
NBNelli Baal
Nelli Baal
SCSarah Cunningham
Sarah Cunningham
HOHannah-Lena Obermann
Hannah-Lena Obermann
JTJenny Thomas
Jenny Thomas
ALAnne Lippitsch
Anne Lippitsch
HHHolger Hackstein
Holger Hackstein
RNA editing by adenosine deaminases acting on dsRNA (ADAR) has become of increasing medical relevance, particularly because aberrant ADAR1 activity has been associated with autoimmunity and malignancies. However, the role of ADAR1 in dendritic cells (DC), representing critical professional APCs, is unknown. We have established conditional murine CD11c Cre-mediated ADAR1 gene ablation, which did not induce general apoptosis in CD11c+ cells but instead manifests in cell type–specific effects in DC subpopulations. Bone marrow–derived DC subset analysis revealed an incapacity to differentiate CD103 DC+ in both bulk bone marrow and purified pre-DC lineage progenitor assays. ADAR1 deficiency further resulted in a preferential systemic loss of CD8+/CD103+ DCs, revealing critical dependency on ADAR1, whereas other DC subpopulations were moderately affected or unaffected. Additionally, alveolar macrophages were depleted and dysfunctional, resembling pulmonary alveolar proteinosis. These results reveal an unrecognized role of ADAR1 in DC subset homeostasis and unveils the cell type–specific effects of RNA editing.

28 October 2020 in Transfusion Medicine and Hemotherapy
Verified
Journal Article
Open access
PDF file
SCSarah Cunningham
Sarah Cunningham
HHHolger Hackstein
Holger Hackstein
Dendritic cells (DCs) are pivotal regulators of immune responses, specialized in antigen presentation and bridging the gap between the innate and adaptive immune system. Due to these key features, DCs have become a pillar of the continuously growing field of cellular therapies. Here we review recent advances in good manufacturing practice strategies and their individual specificities in relation to DC production for clinical applications. These take into account both small-scale experimental approaches as well as automated systems for patient care.

2 July 2019 in Journal of Leukocyte Biology
Verified
Journal Article
Closed access
PDF file
ALAnne Lippitsch
Anne Lippitsch
NBNelli Baal
Nelli Baal
YCYuri Chukovetskyi
Yuri Chukovetskyi
SCSarah Cunningham
Sarah Cunningham
GMGabriela Michel
Gabriela Michel
HHHolger Hackstein
Holger Hackstein

Verified
Journal Article
Open access
PDF file
SCSarah Cunningham
Sarah Cunningham
HHHolger Hackstein
Holger Hackstein
Human umbilical cord blood (UCB) represents a valuable source of hematopoietic stem cells, particularly for patients lacking a matching donor. UCB provides practical advantages, including a lower risk of graft-versus-host-disease and permissive human leukocyte antigen mismatching. These advantageous properties have so far been applied for stem cell, mesenchymal stromal cell, and chimeric antigen receptor T cell therapies. However, UCB-derived professional antigen-presenting cells are increasingly being utilized in the context of immune tolerance and regenerative therapy. Here, we review the cell-specific characteristics as well as recent advancements in UCB-based cell therapies focusing on dendritic cells, monocytes, B lymphocytes, innate lymphoid cells, and macrophages.

14 March 2023 in Journal of Leukocyte Biology
Verified
Journal Article
Open access
PDF file
CHCarl Haberkamp
Carl Haberkamp
IAIda Allabauer
Ida Allabauer
NBNiklas Blaha
Niklas Blaha
BBBarbara Bodendorfer
Barbara Bodendorfer
SCSarah Cunningham
Sarah Cunningham
RLRoland Lang
Roland Lang
TNF blockade constitutes an effective therapy for inflammatory bowel disease (IBD), yet increases the risk for infection including active tuberculosis. The DECTIN2 family C-type lectin receptors (CLR) MINCLE, MCL and DECTIN2 sense mycobacterial ligands and activate myeloid cells. In mice, upregulation of DECTIN2 family CLR after stimulation with Mycobacterium bovis Bacille Calmette-Guerin (BCG) requires TNF. Here, we investigated whether TNF controls inducible CLR expression in human myeloid cells. Monocyte-derived macrophages (MDM) were stimulated with BCG and the TLR4 ligand LPS, and expression of CLR was analyzed. BCG and LPS strongly upregulated mRNA expression of DECTIN2 family CLR, but not of DECTIN1. BCG and LPS also induced robust production of TNF. Recombinant TNF was sufficient to upregulate expression of DECTIN2 family CLR. Blocking TNF with the TNFR2-Fc fusion protein Etanercept abrogated, as expected, the effect of recombinant TNF, and impaired induction of DECTIN2 family CLR by BCG and LPS. Flow cytometry confirmed upregulation of MCL at the protein level by recombinant TNF and showed inhibition of BCG-induced MCL by Etanercept. To investigate the impact of TNF on CLR expression in vivo, we analyzed PBMC of patients with IBD and observed down-regulation of MINCLE and MCL expression after therapeutic TNF blockade. Together, TNF is sufficient to upregulate DECTIN2 family CLR in human myeloid cells and contributes to this process after encounter with BCG or LPS. Impaired CLR expression in patients receiving TNF blockade may dampen the sensing of microbes and defense against infection.